William Sievert

Professor

Professor, Medicine Monash Health
Ctr for Inflam Disease Monash Health

EmailWilliam.Sievert@monash.edu

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor William Sievert is a clinician-scientist with dual appointments at Monash University and Monash Health as the Director of the Gastrointestinal and Liver Unit. Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students.

The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies. He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents.

Professor Sievert is also active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2024

2 Not started
6 Finished
7 Active

A Phase 1, Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of single and multiple doses of ABI-H2158 in Healthy Volunteers; and Multiple-Ascending Dose Pharmacokinetics and pharmacodynamics in Patients with Chronic Hepatitis B Infection

Sievert, W.

20/05/19 → 19/05/24

Project: Research

A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients with Chronic Hepatitis B

Sievert, W.

4/03/19 → 3/03/24

Project: Research

A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218

Sievert, W.

12/02/19 → 11/02/24

Project: Research

A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients

Sievert, W.

1/02/19 → 31/01/24

Project: Research

A spectral and in vitro study of intestinal fibrogenesis and biomarkers in Crohn's disease to inform 3D-human tissue-based models of intestinal fibrosis and identify therapeutic targets

Keung, C., Moore, G., Lim, R., Sievert, W., Heraud, P. & Wood, B.

The Gutsy Group Inc

1/01/19 → 31/12/21

Project: Research

Research Output 1989 2019

98 Article
8 Letter
3 Chapter (Book)
3 Abstract
7 More

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

Nicoll, A. J., Roberts, S. K., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Tse, E., Levy, M., Sood, S., Zekry, A., Cheng, W., Mitchell, J., Skoien, R., Sievert, W., Strasser, S. I., McCaughan, G. W. & 1 otherson behalf of the ALA Clinical Research Network, Gastroenterological Society of Australia, 1 May 2019, In : Alimentary Pharmacology and Therapeutics. 49, 10, p. 1314-1322 9 p.